The current stock price of SMLR is 15.29 USD. In the past month the price decreased by -23.47%. In the past year, price decreased by -74.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.17 | 49.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B |
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Campbell, California and currently employs 79 full-time employees. The company went IPO on 2014-02-27. The firm's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The firm delivers QuantaFlo directly to its customers. The firm also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
SEMLER SCIENTIFIC INC
51 E Campbell Ave, Suite 107-D
Campbell CALIFORNIA 97210 US
CEO: Douglas Murphy-Chutorian
Employees: 79
Phone: 18777744211
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Campbell, California and currently employs 79 full-time employees. The company went IPO on 2014-02-27. The firm's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The firm delivers QuantaFlo directly to its customers. The firm also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
The current stock price of SMLR is 15.29 USD. The price increased by 0.53% in the last trading session.
SMLR does not pay a dividend.
SMLR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
9 analysts have analysed SMLR and the average price target is 66.98 USD. This implies a price increase of 338.06% is expected in the next year compared to the current price of 15.29.
The PE ratio for SEMLER SCIENTIFIC INC (SMLR) is 1.75. This is based on the reported non-GAAP earnings per share of 8.76 and the current share price of 15.29 USD.
SEMLER SCIENTIFIC INC (SMLR) will report earnings on 2026-02-16.
ChartMill assigns a fundamental rating of 4 / 10 to SMLR. There are concerns on the financial health of SMLR while its profitability can be described as average.
Over the last trailing twelve months SMLR reported a non-GAAP Earnings per Share(EPS) of 8.76. The EPS increased by 220.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 130.8% | ||
| ROA | 8.1% | ||
| ROE | 10.51% | ||
| Debt/Equity | 0.25 |
9 analysts have analysed SMLR and the average price target is 66.98 USD. This implies a price increase of 338.06% is expected in the next year compared to the current price of 15.29.
For the next year, analysts expect an EPS growth of -95.59% and a revenue growth -43.2% for SMLR